Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CS-834 (Sankyo).

M L van Ogtrop1

  • 1Department of Medical Microbiology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands. ogtrop@microbiology.azl.nl

Idrugs : the Investigational Drugs Journal
|September 15, 2005
PubMed
Summary

CS-834, an oral carbapenem antibiotic, shows promise for respiratory and urinary tract infections. It demonstrated superior efficacy against common bacteria compared to cephalosporins in mouse models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants.

Microbiology spectrum·2021
Same author

An unusual peripheral blood smear.

The Netherlands journal of medicine·2014
Same author

[Prevention of nosocomial infections after cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine; a prospective, randomised study].

Nederlands tijdschrift voor geneeskunde·2008
Same author

In vivo pharmacodynamics of a new oxazolidinone (linezolid).

Antimicrobial agents and chemotherapy·2002
Same author

The diagnostic value of streptococcal serology in early arthritis: a prospective cohort study.

Rheumatology (Oxford, England)·2001
Same author

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Antimicrobial agents and chemotherapy·2000

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • The development of orally active carbapenems is a significant unmet need in antibacterial therapy.
  • CS-834 is an orally administered prodrug rapidly converted to its active form, R-95867.
  • Currently, no oral carbapenem antibiotics are commercially available.

Purpose of the Study:

  • To evaluate the efficacy of CS-834 as an oral carbapenem antibiotic.
  • To compare the in vivo antibacterial activity of CS-834 with existing cephalosporins.

Main Methods:

  • CS-834 was administered orally to mice.
  • Antibacterial activity was assessed against Gram-positive and Gram-negative bacterial species.
  • Comparison was made with oral cephalosporins, including cefdinir and cefditoren pivoxil.

Main Results:

  • CS-834 exhibited a favorable antibacterial profile against key Gram-positive (e.g., Staphylococcus aureus) and Gram-negative (e.g., Escherichia coli, Klebsiella pneumoniae) pathogens.
  • The compound demonstrated superior efficacy compared to tested cephalosporins in oral administration models.
  • Pseudomonas and Enterococcus species displayed limited susceptibility to CS-834.

Conclusions:

  • CS-834 represents a potential breakthrough in oral carbapenem therapy.
  • Its efficacy in preclinical models suggests promise for treating respiratory and urinary tract infections.
  • Further clinical investigation is warranted, particularly for infections caused by less susceptible organisms.

Related Experiment Videos